On Saturday April 27th 2013, the 2012 Lindy Fraser Memorial Award was presented to Dr. David Goltzman at the annual CaMos meeting in Montreal. Osteoporosis Canada would like to congratulate Dr. Goltzman!
Osteoporosis Canada established this award in 1993. This prestigious award recognizes individuals who have done exemplary research and have helped to increase the knowledge about osteoporosis. The recipient is nominated by members of our Scientific Advisory Council.
Photo (From left to right): Dr. Angela Cheung, Dr. Famida Jiwa and Dr. David Goltzman.
A recent report by the US Preventive Services Task Force (USPSTF) suggests that low doses of vitamin D up to 400 IU daily and calcium supplements up to 1000 mg daily are not effective in reducing the risk of fracture in healthy people (that is, people without osteoporosis or fractures). Based on all research to date, Osteoporosis Canada still recommends that those with osteoporosis or fractures who are 50 years of age or more take 1200 mg of elemental calcium daily, preferably from dietary sources, and 800-2000 IU of a vitamin D supplement daily.
Recently concern has been raised regarding potential increased risk of coronary events in association with calcium supplements. The research studies which have been completed have been relatively small and have been of less than ideal design. Further research with large well designed studies is needed. Osteoporosis Canada recommends that daily intake of calcium be obtained largely from dietary sources. If this is not possible then supplements may be used preferably calcium carbonate or calcium citrate following discussion with your doctor regarding the safe dose for each individual.
Effective December 1st, the Alberta Drug Benefits Listing has included Aclasta under Special Authorization criteria. The Alberta Drug Benefit List defines the prescription drugs and drug products covered by the ministry's supplemental health plans.
Osteoporosis Canada congratulates the Ontario government, the New Brunswick government, the Saskatchewan government and the British Columbia government for providing access to a new osteoporosis medication. Aclasta (zoledronic acid) is now available on public and private drug plans in Ontario, BC, SK, and NB meaning Canadians at high risk for fractures have access to increased treatment options.
**Effective December 1st, the Alberta Drug Benefits Listing has included Aclasta under Special Authorization criteria.